



RETURN BIDS TO:

RETOURNER LES SOUMISSIONS À:

Drugs, Vaccines and Biologics Division/ Division
des produits pharmaceutiques, biologiques et des
vaccins

suzanne.bissonnette@pwgsc.gc.ca

**LETTER OF INTEREST
LETTRE D'INTÉRÊT**

Comments - Commentaires

Vendor/Firm Name and Address

Raison sociale et adresse du
fournisseur/de l'entrepreneur

Issuing Office - Bureau de distribution

Drugs, Vaccines and Biologics Division/Div.des produits
pharmaceutiques,biologiques et de vaccins
Terrasses de la Chaudière 5th Floo
10 Wellington Street
Gatineau
Quebec
K1A 0S5

Title - Sujet Vasopressors	
Solicitation No. - N° de l'invitation E60PH-20VASO/A	Date 2020-04-20
Client Reference No. - N° de référence du client E60PH-20VASO	GETS Ref. No. - N° de réf. de SEAG PW-\$\$PH-895-78666
File No. - N° de dossier ph895.E60PH-20VASO	CCC No./N° CCC - FMS No./N° VME
Solicitation Closes - L'invitation prend fin at - à 02:00 PM on - le 2020-05-08	
Time Zone Fuseau horaire Eastern Daylight Saving Time EDT	
F.O.B. - F.A.B. Specified Herein - Précisé dans les présentes Plant-Usine: <input type="checkbox"/> Destination: <input type="checkbox"/> Other-Autre: <input checked="" type="checkbox"/>	
Address Enquiries to: - Adresser toutes questions à: Bissonnette(ph895), Suzanne	Buyer Id - Id de l'acheteur ph895
Telephone No. - N° de téléphone (819) 360-4895 ()	FAX No. - N° de FAX () -
Destination - of Goods, Services, and Construction: Destination - des biens, services et construction: See Herein	

Instructions: See Herein

Instructions: Voir aux présentes

Delivery Required - Livraison exigée	Delivery Offered - Livraison proposée
Vendor/Firm Name and Address Raison sociale et adresse du fournisseur/de l'entrepreneur	
Telephone No. - N° de téléphone Facsimile No. - N° de télécopieur	
Name and title of person authorized to sign on behalf of Vendor/Firm (type or print) Nom et titre de la personne autorisée à signer au nom du fournisseur/ de l'entrepreneur (taper ou écrire en caractères d'imprimerie)	
Signature	Date

REQUEST FOR INFORMATION RE: Supply and Demand of Norepinephrine

The Government of Canada recognizes that Canadians who are ill with COVID-19 need access to safe and effective medicines and treatments. As such, the Government of Canada is actively monitoring the impact of the COVID-19 pandemic on the supply of drugs in Canada.

Through this Request for Information (RFI), Canada is seeking to collect information from companies on availability of Norepinephrine. This information will be used to inform the Government's response to the ongoing pandemic.

The priority of the Government of Canada is to ensure that there remains a stable supply of Norepinephrine for those patients who require it for treatments as currently approved by Health Canada. Monthly demand for Norepinephrine has typically been 104,700 units for 4mL vials.

Current demand is reported to be two to three times higher than the typical level. This increase has resulted in reported shortages and Health Canada is working with manufacturers, suppliers and distributors to address those shortages.

This request is a tool to identify additional supply that has not already been earmarked to meet Canada's current needs for Norepinephrine. The Government of Canada is interested in procuring up to a twelve-month supply at the elevated demand levels, which would support existing efforts to ensure Canadians have access to the drugs they need. In light of ongoing fluctuations in global and domestic demand, should the Government proceed, an incremental procurement approach would be considered.

Please Note: If your company is currently working with the Government of Canada to address an existing shortage, we are not looking for information on products already identified to mitigate the shortage. The Government of Canada is also interested in receiving information about acceptable substitute drugs.

If your company is not currently working with the Government of Canada to address an existing shortage, or if you are working with Health Canada but may have access to additional product, we would welcome information on available Norepinephrine or equivalent product. We are looking to ensure this drug is available for Canadians without affecting the supply currently available for the Canadian market through existing distribution channels.

The Government of Canada is aware that there are risks of drug shortages globally due to the pandemic and that the current drug shortages faced by Canada are not unique. As such, many jurisdictions are seeking to access the supply from many of the same sources. The Government of Canada remains committed to working with its international partners on the issue of drug shortages to stabilize global supply chains as quickly as possible.

Supply Questions	
The quantity of Norepinephrine available immediately (i.e. within 7 days).	
The additional quantity of Norepinephrine available by May 15, 2020.	
The additional quantity of Norepinephrine available between May 16 and June 30, 2020.	
The additional monthly quantity available July 1, 2020 and beyond.	
Estimated unit price (per XXX) of finished product, including to deliver to final destination.	

Vendor Managed Inventory Questions	
The total quantity of Norepinephrine available that could be vendor held and managed (in Canada) on behalf of the Government of Canada for up to 24 months.	
Inventory must be rotated out to ensure a minimum of 14 months of remaining shelf life.	
Expected hours of operation for shipment requests are Monday to Friday during normal business hours.	
Expected turnaround time for shipment requests (from time request is received to the shipment leaving the depot) is one business day.	
Storage location	
Minimum order size when shipping out of vendor held inventory (if applicable)	
Estimated monthly cost for vendor held and managed inventory (flat rate or per _____ (e.g. units, package, pallet, etc. – please specify) of finished product (if applicable).	

API Questions	
The quantity of API available immediately (i.e. within 7 days) both in metric tons and the approximate number of finished units that could be produced.	
How many units are produced per metric tonne of bulk API?	
What is the shelf life of bulk API?	
What is the production time required to deliver finished products from the date of request to produce from bulk API?	
The additional quantity of API available monthly, May 15, 2020 and beyond	
Estimated price of API per metric tonne	
Estimated additional cost per unit to manufacture from bulk API to finished product, including delivery to final destination	
Estimated monthly cost for vendor held and managed inventory (per metric tonne) of API (if applicable)	

Please specify any caveats of conditions that would apply to the questions provided above. Additionally, for the inventories (units and API) described above, identify what quantities are currently held domestically and what is contingent on being imported into Canada.

Note: This is not a bid solicitation. Potential suppliers of any goods or services described in this RFI should not reserve stock or facilities, nor allocate resources, as a result of any information contained in this RFI. Also, the procurement of any goods and services described in this RFI will not necessarily follow this RFI. This RFI is simply intended to solicit feedback from industry with respect to the matters described in this RFI.

Canada will not reimburse any respondent for expenses incurred in responding to this RFI.

Responses are to be submitted electronically only. No written/hard copies will be accepted. You are requested to submit a response by April 28th, 2020, however submissions may also be accepted until May 8th, 2020. Responses are to be sent by e-mail to suzanne.bissonnette@tpsgc-pwgsc.gc.ca.